We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia.
- Authors
Kulkarni, Uday P.; Selvarajan, Sushil; Lionel, Sharon; Prakash, Mithun A.; Palani, Hamenth Kumar; Balasundaram, Nithya; Venkataraman, Arvind; Korula, Anu; Devasia, Anup J.; Fouzia, N. A.; Janet, Nancy Beryl; Nair, Sukesh Chandran; Abraham, Aby; Mani, Thenmozhi; Lakshmanan, Jeyaseelan; Arunachalam, Arun Kumar; Balasubramanian, Poonkuzhali; George, Biju; Mathews, Vikram
- Abstract
Of the 111 patients who attained morphologic CR after induction, 2 patients were lost to follow-up. 3 show the clinical characteristics and survival of 28 patients with low-risk APL who were excluded from the analysis since they received single agent ATO during induction therapy. Four (3.3%) patients were discharged against medical advice beyond 2 weeks of treatment but before completing induction and were clinically well at discharge, opting to continue treatment at another center. B Dear Editor b , Multiple studies have established the synergy between ATO and ATRA in APL, and a combination of these drugs without chemotherapy is the new standard of care in low and intermediate-risk patients [[1]-[5]].
- Subjects
ACUTE promyelocytic leukemia; ARSENIC trioxide; TRETINOIN; MEDICAL care
- Publication
Blood Cancer Journal, 2022, Vol 12, Issue 1, p1
- ISSN
2044-5385
- Publication type
Letter
- DOI
10.1038/s41408-022-00619-3